Clinical trials
Phase 2 Myocardial Ischemia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 4 |
| 2014 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Terminated | 3 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
| Cytori Therapeutics | 2 |
| Abbott Medical Devices | 1 |
| Akiva Mintz | 1 |
| Avant Immunotherapeutics | 1 |
| Cedars-Sinai Medical Center | 1 |
| Fluoropharma, Inc. | 1 |
| Forest Laboratories | 1 |
| GE Healthcare | 1 |
| Hospital for Special Surgery, New York | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myocardial Ischemia | 27 |
| Coronary Artery Disease | 13 |
| Cardiovascular Diseases | 8 |
| Coronary Disease | 8 |
| Heart Diseases | 5 |
| Myocardial Infarction | 4 |
| Vascular Diseases | 4 |
| Angina Pectoris | 3 |
| Arterial Occlusive Diseases | 3 |
| Arteriosclerosis | 3 |
Trials
Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.